On the stock market since 2015, it operates in the world of health and science. It has 38 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 43% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $169.8M against $1.3M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 103 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, CDTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CDTX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.